Names : Juvenile xanthogranuloma (JXG); belongs to the group of non-Langerhans histiocytosis (NLCH).
First description : Adamson, 1905 (“congenital xanthoma multiplex”); the modern nomenclature was consolidated in the mid-twentieth century.
Epidemiology : Predominant in infants and young children; typically first appears within the first two years of life; may be congenital. Typical benign cutaneous course with spontaneous involution.
Current classification : Included in the histiocytosis family (group C/NLCH) and in histiocytic and dendritic tumors according to the Histiocyte Society/WHO review.
Codes : ICD-10 : D76.3 (other histiocytoses); ICD-11 : 2B31.0 (Juvenile xanthogranuloma).
Search for disease
Directory of diseases
Created: 27/11/2025
Last updated: 09/12/2025
Important: This content is for informational purposes only and is intended for healthcare professionals. It does not replace clinical assessment or medical judgment, does not establish a doctor-patient relationship, and does not constitute a standard of care. Medicine is rapidly evolving: always verify sources and use this information only as additional input for decision-making.Juvenile xanthogranuloma
General
- Proliferation of histiocytes (dermal/factor XIIIa+) with a variable inflammatory response; in most cutaneous cases, it is self-limiting. Activating alterations in pathways MAPK/ERK and, in extracutaneous subgroups, alterations CSF1R, ALK and mergers CLTC::SYK/NTRK1 have been described (therapeutic implications in systemic/atypical cases).
Elementary lesion : Firm, well-defined, dome-shaped papule or nodule, yellow-orange/erythematous in color; sometimes with superficial telangiectasias. “ Eruptive ” when multiple.
Typical areas : Face, neck, trunk; may affect mucosa (oral), subcutis, and, infrequently, viscera/CNS (systemic).
Prototypical clinical presentation : Child <2 years with a single lesion; evolution from reddish to yellow, with involution in 1–5 years leaving hyperpigmentation or mild atrophy.
Additional findings : Dermoscopy with " sunset " pattern (yellow-orange central disc with erythematous halo) and linear/branched vessels; not exclusive to JXG.
Evolution : Self-limited in most cutaneous forms; deep/multiple forms may persist; ocular (iris) JXG may produce hyphema/glaucoma.
Atypical forms : Giant/plaque, multiple/disseminated, subcutaneous/intramuscular (“deep”), mucosal (oral), visceral, CNS-JXG (Central Nervous System)
- Spitz nevus/ Spitzoid melanocytic nevus
- mast cell tumor,
- dermatofibroma,
- xanthomas (dyslipidemias),
- hemangioma,
- neurofibroma,
- Langerhans cell histiocytosis (LCH).
Pattern : Granulomatous/xanthogranulomatous dermatitis with foamy histiocytes and Touton giant cells ; variable lymphoeosinophilic infiltrate; epidermis usually spared.
IHC (immunohistochemistry) : CD68 , CD163 , factor XIIIa , fasciol positive / CD1a , langerin (CD207) negative / S100 usually negative or weak (may be positive in rare cases).
Special stains/DIF (direct immunofluorescence) : Not routinely required.
Molecular tests (when atypical/systemic) : Search for BRAFV600E (most relevant in CNS-JXG/overlapping entities), ALK (FISH/NGS), CSF1R , NTRK1 , CLTC::SYK fusions.
- Langerhans Cell Histiocytosis (LCH) (CD1a+/langerin+, Birbeck),
- Reticulohistiocytoma
- Erdheim-Chester, Rosai-Dorfman (S100++ with emperipolesis),
- Dermatofibroma (factor XIIIa+, but without Touton or typical xanthomization),
- Necrobiotic xanthogranuloma
Typical solitary cutaneous : No further studies required.
Multiple/atypical/systemic symptoms : Complete blood count , liver function tests, abdominal ultrasound, chest X-ray; targeted MRI if neurological symptoms; ophthalmology if <2 years with multiple lesions or head/neck lesions or any ocular signs. Universal ocular screening is not necessary for single lesions and lesions distant from the eye.
Biopsy:
Type : Deep punch or excisional including dermis and superficial subcutis; ideal in “active” (non-involutive) lesions.
Considerations : Discontinue previous irritating topical treatments if possible; avoid ulcerated/old areas; fix in 10% formalin for HE/IHC; routine IFD is not required.
Contraindications : Relative (coagulopathy, ocular location with risk of hyphema).
First line (typical cutaneous) : Watchful waiting ; family education. Excision if diagnosis is uncertain, bleeding occurs, ulceration is present, or there is an aesthetic/functional impact.
Local options (selected): Laser (e.g., CO₂/ablative or pulsed dye) in special variants (giant plaque, sequelae) and excision ; evidence based on series/cases.
Ocular JXG : Topical/periocular/systemic corticosteroids, management of hyphema/glaucoma ; surgery if refractory. Visual prognosis is better with early treatment.
Systemic/extracutaneous JXG (SJXG) : Regimens taken from LCH (e.g., vinblastine + prednisone ), cytarabine , cladribine ; oral/topical sirolimus (case/series data); targeted therapies if target mutations are present (e.g., ALK inhibitors such as alectinib in ALK-+; imatinib reported in CSF1R -mutated CNS-JXG). Individualize treatment in experienced centers.
Precautions/Safety : Vinblastine (neuro/myelotoxicity), cytarabine (myelosuppression), cladribine (lymphopenia/infections), sirolimus (dyslipidemia, stomatitis, immunosuppression), ALK-i (hepatotoxicity, bradycardia), imatinib (edema, hepatotoxicity, cytopenias). (Based on monographs and series; select according to mutations and extent).
Ocular signs (photophobia, epiphora, hyphema): refer to ophthalmology immediately.
Multiple or deep lesions or systemic symptoms (fever, weight loss, hepatosplenomegaly, neurological symptoms): request basic and imaging studies.
Child with NF1 (neurofibromatosis type 1) + JXG: association described with JMML (juvenile myelomonocytic leukemia) ; although the absolute risk is low and debated, maintain high clinical and hematological surveillance.
JXG in CNS or visceral: management in units with experience in pediatric/hemato-oncological histiocytosis; consider molecular profiling (possible targeted therapy).
Touton + CD68/CD163/factor XIIIa positive and CD1a/langerin negative strongly orient JXG vs LCH.
The dermatoscopic pattern “ sunset ” supports the diagnosis but is not exclusive.
Most skin lesions resolve without treatment within 1–5 years.
Dehner LP. Juvenile xanthogranulomas in the first two decades of life… Am J Surg Pathol. 2003;27:579–593. DOI: not available · **PMID:**12717244. Abstract: Series of 174 cases characterizing cutaneous and extracutaneous spectrum, morphology (Touton), course and complications.
Hernández-Martín A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol. 1997;36:355–367. **DOI:**10.1016/S0190-9622(97)80207-1 · **PMID:**9091465. Summary: Classic clinical review of presentation, evolution and histology of JXG.
So JTY, et al. Juvenile xanthogranuloma: a review with updates on the pathogenesis, associations… Pediatr Dermatol. 2020;37:xxx–xxx. DOI: not available · **PMID:**32468628. Abstract: Modern review with recommendations for screening/follow-up and management.
Emile JF, et al. Revised classification of histiocytoses… Blood. 2016;127:2672–2681. **DOI:**10.1182/blood-2016-01-690636 · **PMID:**26966089. Abstract: Current classification framework of histiocytosis (includes JXG).
Tahan SR, et al. Juvenile xanthogranuloma. J Am Acad Dermatol. 1989;20:xxx–xxx. DOI: not available · **PMID:**2505733. Abstract: Clinicopathological characterization of typical skin lesions.
Nascimento AF, et al. Juvenile xanthogranuloma: comparative clinicopathologic study… Am J Surg Pathol. 1999/1997. DOI: not available · **PMID:**9199641. Abstract: Deep subtypes (subcutaneous/intramuscular) and their differential histology.
Newman CC, et al. Nonlipidized juvenile xanthogranuloma… Am J Surg Pathol. 1997;21:xxx–xxx. DOI: not available · **PMID:**9144693. Abstract: Nonlipidized variant that can mimic aggressive neoplasms; IHC key.
Samara WA, et al. Juvenile Xanthogranuloma of the iris: clinical features/outcomes… Ophthalmology. 2015;122:xxxx. DOI: not available · **PMID:**26189188. Abstract: Large ophthalmologic series: complications (hyphema, glaucoma) and visual outcomes.
Freyer DR, et al. Juvenile xanthogranuloma: forms of systemic disease… J Pediatr. 1996;129:227–237. DOI: not available · **PMID:**8765620. Abstract: Classic description of SJXG, organ distribution, and therapeutic considerations.
Zou T, et al. Systemic juvenile xanthogranuloma: a systematic review. Pediatr Blood Cancer. 2023;70:e30232. **DOI:**10.1002/pbc.30232 · **PMID:**36779547. Abstract: Modern systematic review of SJXG: profiles, treatments, and outcomes.
Kemps PG, et al. Recurrent CLTC::SYK fusions and CSF1R mutations in JXG of soft tissue. Blood. 2024;144:2439–2455. **DOI:**10.1182/blood.2024025127 · **PMID:**39316650. Abstract: Cohort with frequent target alterations in extracutaneous JXG; therapeutic implications.
Durham BH, et al. Activating mutations in CSF1R … Nat Med. 2019;25:1839–1842. **DOI:**10.1038/s41591-019-0653-6 · **PMID:**31768065. Abstract: Mutations in CSF1R/RTKs in histiocytosis; responses to selective inhibitors.
Picarsic J, et al. BRAFV600E in CNS-JXG: revised algorithm… Acta Neuropathol Commun. 2019;7:168. **DOI:**10.1186/s40478-019-0811-6 · **PMID:**31685033. Summary: High rate of BRAF in pediatric CNS JXG; diagnostic guide.
Xu J, et al. Systemic JXG has higher frequency of ALK translocations than BRAFV600E . J Am Acad Dermatol. 2023;88:656–659. **DOI:**10.1016/j.jaad.2020.08.053 · **PMID:**32822792. Summary: Points out role of ALK in SJXG and option of ALK-i therapies.
Pretel M, et al. Dermoscopic “setting sun” pattern of JXG. J Am Acad Dermatol. 2015;72:S73–S75. **DOI:**10.1016/j.jaad.2014.09.042 · **PMID:**25500052. Abstract: Describes the classic dermatoscopic pattern.
Xu J, et al. Dermoscopic patterns in JXG (series n=41). Front Med (Lausanne). 2021;7:618946. **DOI:**10.3389/fmed.2020.618946 · **PMID:**33521026. Abstract: Dermoscopy-histology correlation by stage; usefulness in follow-up.
Toker M, et al. Oral sirolimus for JXG (2 cases). [Journal] 2024. DOI: not available · **PMID:**38444069. Abstract: Rapid clinical response; suggests role of the mTOR axis in JXG.
Martínez-Torres V, et al. CNS-JXG with mutated CSF1R , response to imatinib . Neuro Oncol. 2024. DOI: not available · PMID: not available (PMCID available). Abstract: First sustained response to imatinib in CSF1R-mutated CNS.
Samara WA, et al. (reiterated in 8) – ocular management and outcomes. (see 8)
Höck M, et al. Various clinical spectra of JXG: 2 cases + review. BMC Pediatr. 2019;19:xxx. **DOI:**10.1186/s12887-019-1490-y · PMID: not available on page, indexed in PubMed Central. Abstract: Expands spectrum, immunophenotype and imaging.
|